鉴定TLRs作为肺腺癌的潜在预后生物标志物
Junjie Ying1, Haihua Hong2, Chaoqun Yu3
1Department of Thoracic Surgery, The People's Hospital of Beilun District, Ningbo, China.
Medicine
|September 25, 2023
概括
收费类受体 (TLRs) 在肺腺癌 (LUAD) 中表达的变化. 特定的TLRs (TLR2/7/8) 可能作为有价值的预后生物标志物来改善LUAD患者的结果.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 分子生物学分子生物学
背景情况:
- 肺腺癌 (LUAD) 是全球癌症死亡的主要原因.
- 异常的托尔类受体 (TLR) 表达与癌症的发展和免疫反应有关.
- 在LUAD中TLRs的预后和治疗作用仍然不完全理解.
研究的目的:
- 为了研究LUAD组织中TLRs的表达模式.
- 分析TLR表达与患者存活率和临床进展之间的相关性.
- 在LUAD中探索TLRs作为预后生物标志物和免疫治疗点的潜力.
主要方法:
- 使用的公共数据库 (ONCOMINE,UALCAN,GEPIA,卡普兰-梅尔绘图器等) 用于数据挖掘.
- 在LUAD和正常组织之间比较TLR的转录水平.
- 分析了TLR表达,突变状态,免疫透和患者生存结果之间的相关性.
主要成果:
- 在LUAD中,TLR1/2/3/4/5/7/8表达显著下降,而TLR6/9/10在LUAD中升高.
- 低TLR1/2/3/5/8表达和高TLR9表达与整体存活率差相关.
- 较低的TLR2/3/7表达与较差的无进展生存率有关.
- TLR1/2/7/8水平与免疫透有显著的相关性.
- TLR信号通路参与了免疫和炎症反应,以及PI3K-Akt信号传递.
结论:
- 在LUAD中,TLR表达特征显著改变.
- TLR2,TLR7和TLR8显示出作为LUAD预后生物标志物的潜力.
- 了解TLR角色可能为LUAD免疫疗法策略提供见解.
相关概念视频
lncRNA - Long Non-coding RNAs
8.6K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.6K
Non-LTR Retrotransposons
11.6K
As the name suggests, non-LTR retrotransposons lack the long terminal repeats characteristic of the LTR retrotransposons. Additionally, both LTR and non-LTR retrotransposons use distinct mechanisms of mobilization. Non-LTR retrotransposons are further divided into two classes - Long interspersed nuclear elements (LINEs) and short interspersed nuclear elements (SINEs), both of which occur abundantly in most mammals, including humans. Some of the active non-LTR retrotransposons in humans are L1...
11.6K


